Davy forecasts 18% revenues leap for Tysabri

Stockbroker Davy has said US Q4 revenues for Elan drug Tysabri could be 18% ahead of forecasts.

Using latest IMS Health sales data for October and November, Davy has estimated that Q4 Tysabri revenues could come in around $97m (€66m), which would be 18% ahead of our forecasts of $82m (€56m).